RadNet guides $140M+ ARR, lifts imaging revenue by $30M (RDNT)

RadNet (RDNT) reported record first-quarter 2026 revenue and EBITDA, raised full-year imaging center revenue guidance by $30 million, and set a DeepHealth annual recurring revenue (ARR) target of more than $140 million for 2026. The quarterly print serves as both a fundamental confirmation for the core imaging business and a potential repricing trigger for the AI diagnostics unit that the market has treated as an option value inside the consolidated multiple.

Q1 Records and the Cash Engine

RadNet’s record Q1 revenue and EBITDA come during what is typically a seasonally lighter period for healthcare utilization. The beat reflects sustained procedure demand, a favorable mix shift toward higher-reimbursement PET/CT scans, and the growing contribution from newly opened or acquired centers. The margin performance provides a cushion against staffing and supply cost pressures while funding the capacity expansion that underlies the full-year guidance lift.

Imaging Center Guidance Raised by $30M

Management raised full-year 2026 imaging center revenue guidance by $30 million. A raise of this size signals confidence that Q1’s volume trends are durable and that commercial and Medicare reimbursement rates remain supportive. Imaging center revenue is the cash-generating foundation of RadNet’s model, funding both debt service and growth initiatives. A $30 million increase flows directly into EBITDA and free cash flow projections, compressing the valuation multiple on a forward basis and lowering the risk of a mid-year guidance reset.

Our stock market analysis indicates that healthcare services companies with visible volume growth tend to sustain valuation premiums when interest rate expectations stabilize. RadNet’s updated guidance embeds a wider margin of safety than the prior range, though staffing and capital deployment remain the day-to-day execution risks.

DeepHealth ARR Above $140M Separates the AI Diagnostics Unit

The second part of the report is the DeepHealth ARR target. Management now expects the AI-powered diagnostic software segment to generate more than $140 million in ARR in 2026. DeepHealth focuses on mammography and lung screening, selling into enterprise healthcare systems where adoption can create high-margin, recurring revenue streams.

The simple market read is that DeepHealth is a growth driver. The practical market read is that a $140M+ ARR target is large enough to support a standalone software valuation that the consolidated RadNet multiple does not currently reflect. Most of the company’s enterprise value is priced around the imaging center asset, implying investors assign negligible standalone value to DeepHealth. Achieving that ARR threshold would force analysts to reconsider a sum-of-the-parts framework.

The execution path is steep. The $140M+ target requires a sharp increase in contract signings and widespread adoption of AI diagnostics by health systems. Unlike the concentration risk in Asia’s AI chip rally, as detailed in our analysis of Korea and Taiwan equity markets, RadNet’s AI revenue stream is tied to medical necessity, not hardware supply cycles. The ramp remains execution-heavy; the outcome depends more on contractor visibility than on silicon shipments.

For RadNet, each quarterly update on DeepHealth ARR growth becomes a direct catalyst. The next major decision point is the second-quarter 2026 earnings report, when management will disclose new contract wins and update the ARR trajectory. Confirmation that the $140M+ target is on track would strengthen the repricing argument; signs of slower enterprise adoption would pressure the multiple expansion thesis. The catalyst chain now runs through DeepHealth’s ARR progression, with Medicare reimbursement updates acting as a secondary trigger.